Potential therapeutic target in AML.WEE1 is a mediator of AML cell survival after cytarabine exposure [93].Ex vivo inhibition of WEE1 and CHK1 synergistically enhanced therapeutic efficacy in AML [94].Combination of Wee1 inhibitor and cytarabine enhanced anti-leukemic effects in mice with AML [95]. Here, WEE1 is linked to acute myeloid leukemia.